Livforsakringsbolaget Skandia Omsesidigt Purchases 27,700 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Livforsakringsbolaget Skandia Omsesidigt increased its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 6,925.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 28,100 shares of the biotechnology company’s stock after acquiring an additional 27,700 shares during the period. Livforsakringsbolaget Skandia Omsesidigt’s holdings in United Therapeutics were worth $9,904,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. USA Financial Formulas bought a new position in shares of United Therapeutics in the 3rd quarter worth $33,000. Brooklyn Investment Group bought a new position in shares of United Therapeutics in the 3rd quarter worth $33,000. Capital Performance Advisors LLP bought a new position in shares of United Therapeutics in the 3rd quarter worth $82,000. MassMutual Private Wealth & Trust FSB increased its holdings in shares of United Therapeutics by 31.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock worth $85,000 after buying an additional 58 shares during the last quarter. Finally, Values First Advisors Inc. bought a new position in shares of United Therapeutics in the 3rd quarter worth $90,000. Institutional investors own 94.08% of the company’s stock.

Insider Buying and Selling at United Therapeutics

In other news, COO Michael Benkowitz sold 15,000 shares of the firm’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $407.32, for a total value of $6,109,800.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Judy D. Olian sold 1,750 shares of the firm’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $412.48, for a total transaction of $721,840.00. Following the completion of the sale, the director now directly owns 5,655 shares of the company’s stock, valued at approximately $2,332,574.40. This represents a 23.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 128,614 shares of company stock valued at $47,868,005 in the last quarter. Company insiders own 11.90% of the company’s stock.

United Therapeutics Stock Down 0.1 %

Shares of UTHR opened at $353.75 on Friday. The stock has a market capitalization of $15.79 billion, a P/E ratio of 15.54, a PEG ratio of 0.92 and a beta of 0.57. The firm has a fifty day simple moving average of $363.31 and a two-hundred day simple moving average of $357.63. United Therapeutics Co. has a twelve month low of $208.62 and a twelve month high of $417.82.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on UTHR shares. TD Cowen increased their price target on shares of United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Oppenheimer increased their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. HC Wainwright increased their target price on shares of United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a report on Thursday, October 31st. UBS Group increased their target price on shares of United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. Finally, LADENBURG THALM/SH SH increased their target price on shares of United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a report on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $382.08.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.